NEW YORK, April 24, 2017 /PRNewswire/ --
On Friday, April 21, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Seven out of nine sectors ended last Friday's trading session in bearish territories. Taking into consideration last Friday's market sentiment, Stock-Callers.com assessed the following Biotechnology equities this morning: ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), TG Therapeutics Inc. (NASDAQ: TGTX), and Esperion Therapeutics Inc. (NASDAQ: ESPR). Download the free research reports on these stocks today: http://stock-callers.com/registration
On Friday, shares in San Diego, California headquartered ACADIA Pharmaceuticals Inc. ended the session 1.17% lower at $32.21 with a total volume of 1.03 million shares traded. ACADIA Pharma's shares have advanced 3.84% in the past three months. The stock is trading 0.87% above its 200-day moving average. Moreover, shares of the Company, which focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders, have a Relative Strength Index (RSI) of 32.91. See our free and comprehensive research report on ACAD at: http://stock-callers.com/registration/?symbol=ACAD
On Friday, shares in New Haven, Connecticut headquartered Alexion Pharmaceuticals Inc. recorded a trading volume of 2.04 million shares, which was higher than their three months average volume of 1.91 million shares. The stock ended the day 1.60% lower at $116.82. Shares of the Company, which develops and commercializes life-transforming therapeutic products, are trading at a PE ratio of 66.37. The Company's shares are trading below its 50-day and 200-day moving averages by 5.82% and 7.40%, respectively. Furthermore, Alexion Pharma's shares have an RSI of 41.77.
On March 30th, 2017, research firm UBS initiated a 'Buy' rating on the Company's stock, with a target price of $138 per share. ALXN free research report PDF is just a click away at: http://stock-callers.com/registration/?symbol=ALXN
New York headquartered TG Therapeutics Inc.'s stock finished Friday's session 1.44% lower at $10.30 with a total volume of 1.12 million shares traded. Over the last three months and the previous one year, TG Therapeutics' shares have gained 145.24% and 1.63%, respectively. Shares of the Company, which focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases primarily in the US, are trading above its 50-day and 200-day moving averages by 11.50% and 52.71%, respectively. TG Therapeutics' stock has an RSI of 52.36. Sign up for your complimentary report on TGTX at: http://stock-callers.com/registration/?symbol=TGTX
Ann Arbor, Michigan headquartered Esperion Therapeutics Inc.'s stock fell 1.85%, to close the day at $36.69. The stock recorded a trading volume of 528,042 shares. Esperion Therapeutics' shares have rallied 231.14% in the previous three months and 91.69% in the past one year. Shares of the Company, which focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol, are trading 16.16% and 118.47% above its 50-day and 200-day moving averages, respectively. Additionally, the stock has an RSI of 55.33.
On March 30th, 2017, research firm UBS upgraded the Company's stock rating from 'Neutral' to 'Buy' while revising its previous target price from $23 a share to $52 a share. Register for free on Stock-Callers.com and download the latest research report on ESPR at: http://stock-callers.com/registration/?symbol=ESPR
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +44-330-808-3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA